Essential Cancer Research - on demand
Time-sensitive and reliable cancer news, research and analysis
covering clinical trials, drugs, treatments and cures worldwide
| For 24/7 unlimited access... | |
|---|---|
Subscribe now
|
or call us on: +43 (0)1 71 72 8 900 (Vienna) or on: +44 (0)20 7769 6707 (London) |
Pricing
Our pricing options are simple. There is one structure for corporates/professionals, and another special discounted structure for patients and their family.
1. Corporates/Professionals (Healthcare & Pharmaceutical)
For corporates/professionals the service costs €720/£720 a year per user. This works out at €60/£60 a month per user.
Corporates/professionals can subscribe to Cancer Stat by contacting us directly:
- by email: cancerstat@templetonapus.com
- by phone:
Vienna office, Austria, European Union: +43 (0)1 71 71 8 900
London office, United Kingdom: +44 (0)20 7769 6707
You have the option of taking a 3 week free trial to Cancer Stat before subscribing.
2. Patients/Family
Patients/family can subscribe to Cancer Stat at a special discounted rate by either of the following methods:
a. Making a single payment of £240 for a year's subscription via PayPal.
b. Paying £30 a month for an ongoing monthly subscription via PayPal.
Both options provide you with your own personal Cancer Stat account and can be found at: www.cancerstat.com/accounts/subscribe
You will have full access to all platform features and to the extensive email services. You can also request that drugs or treatments that are of special interest to you are added and tracked.
After signing up:
1. You will receive by email your login ID and password within 3 hours.
2. The email will include a weblink with a 10 minute video demo explaining how to most effectively use your Cancer Stat account.
3. You will be asked in the email if you have any specific information content requests.
Payments
1. Corporates/Professionals (Healthcare & Pharmaceutical)
Corporates/professionals will be invoiced.
2. Patients/Family
Patients/family can make secure payments using credit or debit cards via PayPal at: www.cancerstat.com/accounts/subscribe
Most viewed
- 1. FDA Grants Bionaut Labs Orphan Drug Designation to BNL-101 for the Treatment of Malignant Gliomas in Pediatric and Adult Patients
- 2. Abata hopes to find ‘perfect fit' with MS cell therapy after $95M series A
- 3. Simplex Health Accelerates Growth With Key Executive Hires
- 4. Starchy snacks may increase CVD risk; fruits and veggies at certain meals decreases risk
- 5. Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
- 6. Korea's ST Pharm aims to launch home-grown mRNA vaccine next year: CEO
- 7. Strand Therapeutics Raises $52M in Oversubscribed Series A Round
- 8. HUTCHMED Announces Pricing of Global Offering
- 9. AstraZeneca, HutchMed's Orpathys scores first global nod in China for rare type of NSCLC
- 10. GlaxoSmithKline shoots for $46B in 2031 sales. But will 'change agent' Walmsley be around to lead the new company?
Last updated at 8:32 GMT
Hot News Makers
Health/Pharma Companies
-
70344.66
-
33275.62
-
31345.15
-
29398.30
-
26932.63
-
15064.11
-
14034.55
-
11235.47
-
10286.63
-
8641.95
Last updated at 8:10 GMT
© Copyright 2021 Templeton Apus. All rights reserved.
Made with 
and
in the EU & the UK
and
in the EU & the UK